We first examined CD82 expression levels in three prostate cancer cell lines derived from metastatic sites in prostate cancer patients, LNCaP from a lymph node metastasis, DU145 from a bone metastasis, and PC3 from a brain metastasis. Here, CD82 is linked to prostate carcinoma.